Market Access News | pharmaphorum

News

Gilead claims first FDA nod for a hepatitis D therapy

At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.

News

Oral Wegovy backed by CHMP at May meeting

The CHMP recommended eight new medicines and 13 line extensions at its May meeting, including Novo Nordisk's oral weight loss therapy.

News

NICE changes stance on Genmab's cervical cancer drug

After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.

News

Bayer gets swift review for Kerendia in type 1 diabetes

FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

News

European study shows inequality in access to new medicines

Trade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US's Most-Favoured Nation (MFN) policy.

News

SCOTUS won't hear pharma's IRA complaints

The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.

Gilead claims first FDA nod for a hepatitis D therapy

Oral Wegovy backed by CHMP at May meeting

NICE changes stance on Genmab's cervical cancer drug

Bayer gets swift review for Kerendia in type 1 diabetes

European study shows inequality in access to new medicines

SCOTUS won't hear pharma's IRA complaints

Trustworthy and novel AI in clinical trial planning, with Kr...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks